Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity Post author: Post published:February 15, 2024 Post category:uncategorized Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC). You Might Also Like Lifetime risk of atrial fibrillation rises to nearly 31% in recent decade April 17, 2024 AI revolutionizes cancer research with advanced tools December 13, 2024 A healthy lifestyle may counteract diabetes-associated brain aging August 28, 2024